Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of 610 in Chinese Adult Subjects With Severe Eosinophilic Asthma

NCT06323213 is registered in ClinicalTrials.gov with Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT06323213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06323213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of 610 in Chinese Adult Subjects With Severe Eosinophilic Asthma
Lead sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
June 24, 2024
Completion date
September 30, 2027
Enrollment
480 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma